Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 12 I, 2000, Pages 1347-1354

  Stangier, J ^a   Su, C A P F ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN II ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; TELMISARTAN;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG URINE LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0033731288     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease
2. Historical perspective on renin system blockade in the treatment of hypertension
3. Angiotensin-converting enzyme inhibitors in the treatment of hypertension
4. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors
5. Adverse effects of the angiotensin-converting enzyme inhibitors
6. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema
7. Angiotensin receptors and their antagonists
8. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure-activity relationships
9. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist BIBR 277
10. Angiotensin-II-receptors: New targets for antihypertensive therapy
11. Angiotensin II receptor blockade in TGR(mREN2)27: Effects of reninangiotensin-system gene expression and cardiovascular functions
12. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade
13. 1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain
14. 14C]telmisartan in healthy volunteers
15. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients
16. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension
17. Telmisartan
18. Assessing the safety profile of a new antihypertensive agent
19. Pharmacological aspects of calcium channel blockers
20. Amlodipine: An overview of its pharmacodynamic and pharmacokinetic properties
21. Bioavailability and bioequivalence of pharmaceutical formulations
22. Update on the statistical analysis of bioequivalence studies
23. Review of methods and criteria for the evaluation of bioequivalence studies
24. A distribution-free procedure for the statistical analysis of bioequivalence studies
25. Clinical pharmacokinetics of amlodipine
26. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension
27. Pharmacokinetics and pharmacodynamics of amlodipine
28. Amlodipine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease
29. Amlodipine: A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease